Statement: the primary trial only records GI adverse events.
Primary_evidence: Adverse Events 1:   Total: 67/349 (19.20%)   Anaemia * 3/349 (0.86%)   Leukopenia * 1/349 (0.29%)   Neutropenia * 3/349 (0.86%)   Thrombocytopenia * 1/349 (0.29%)   Atrial fibrillation * 2/349 (0.57%)   Cardiac arrest * 1/349 (0.29%)   Cardiac failure * 0/349 (0.00%)   Cardiac failure acute * 0/349 (0.00%)   Cardio-respiratory arrest * 2/349 (0.57%)   Cardiovascular insufficiency * 0/349 (0.00%) Adverse Events 2:   Total: 69/353 (19.55%)   Anaemia * 2/353 (0.57%)   Leukopenia * 1/353 (0.28%)   Neutropenia * 1/353 (0.28%)   Thrombocytopenia * 1/353 (0.28%)   Atrial fibrillation * 0/353 (0.00%)   Cardiac arrest * 1/353 (0.28%)   Cardiac failure * 4/353 (1.13%)   Cardiac failure acute * 1/353 (0.28%)   Cardio-respiratory arrest * 0/353 (0.00%)   Cardiovascular insufficiency * 1/353 (0.28%)